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MILD TRAUMATIC BRAIN INJURY AND POST TRAUMATIC EPILEPSY: 
BIOLOGICAL RELEVANCE AND STRATEGIES FOR TREATMENT 
PAUL CASTLE MACMULLIN 
ABSTRACT 
Intro: There is mounting evidence to suggest a causal link between mild 
traumatic brain injury (mTBI) and post traumatic epilepsy (PTE). Significant ranges in 
the methods and definitions of “mild” TBI, each with their own limitations, make 
drawing cohesive conclusions from the state of the literature difficult. However, this body 
of work attempts to compile the literature in order to better elucidate the relationship 
between these populations. Ultimately, I hope this source to be a useful reference for 
understanding the state of the research such that one can make critical considerations in 
the future design of methods to definitively improve the quality of work in this field. 
Meaningful improvements could radically improve the outcomes for the millions of 
people who suffer as a result of these injuries and their lasting implications. 
Methods: PubMed searches used keywords: Traumatic Brain injury (mild), 
Epilepsy, Concussion, Loss of cortical inhibition, Post Traumatic Epilepsy. Combinations 
of terms including mTBI or PTE AND MRI, fMRI, DTI, MRS, Biomarkers, TMS, EEG, 
and pathology. 
Results: Strong trends persist despite the limitation in consistency of terminology 
and methods. Relative risk scores between 1.5 and 2.2 percent have been established 
across multiple long-term studies across decades of research and millions of person years, 
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a 2-3-fold change over the baseline incidence of epilepsy in the general population (0.7%; 
less than one in every 100). 
Preclinical studies in mice have recently shown progressive increased seizure 
susceptibility after repeated mTBI. Within the first three weeks after injury, Glutamate 
homeostasis is altered meaningfully. Increased neural excitability results as the balance 
between excitation and inhibition shifts in the brain. An increased Glu/GABA ratio has 
also been linked to dysfunction in GABAergic cell populations, including parvalbumin 
positive inhibitory interneurons (PVI). Oxidative stress, as measured by a decreased 
GSH/GSSG ratio, suggests a dysregulation in homeostatic processes than can outlive 
clinical symptoms. Animals also display a decreased latency to induced seizure by 
Pentelynetetrazole (PTZ) a potent GABA receptor antagonist. Six weeks after injury, 
these mice have been shown to display; decreased GABA driving an increased 
Glu/GABA ratio, decreased EEG gamma power, and prominent signs of gliosis involving 
both astrocytes and microglia.  
Clinical investigations into the biology of this injury, utilizing a wide range of 
techniques, point to a loss of cortical inhibitory tone, an early hallmark of PTE. TMS 
findings of both reduced resting motor threshold and a shorter cortical silent period 
suggest a loss of cortical inhibitory tone likely shifting the excitation/inhibition balance. 
Signs of microstructural damage and altered cell permeability point to a disruption in 
chemical gradients which leads to greater functional deficits, as the parameters for 
normal cell function are no longer maintained. Changes in function and metabolism have 
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been shown to outlast many of the behavioral and acute clinical symptoms suggesting a 
slow development but long duration of this insidious process. 
Conclusion: Mechanisms that link mTBI to PTE include a loss of cortical 
inhibition, increased oxidative stress and gliosis which over time increases Glu/GABA 
ratio, in turn increasing the likelihood of developing epilepsy. Although the relationship 
between mTBI and PTE has been suggested before through epidemiological studies, there 
is now emerging biochemical evidence to better describe this connection. Due to the high 
incidence of mTBI, any small increase in risk to develop PTE pursuant to concussion will 
affect millions of lives. With this new evidence, treatments can be designed to halt the 
progression and alleviate symptoms for those afflicted. The investigation of the biological 
mechanisms that link concussion and epilepsy is a critical step in developing treatment 
strategies and prophylaxis that could prove to be crucial for so many. 
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Approximately 3.8 million people sustain a mild traumatic brain injury (mTBI) 
each year in the United States.92 While the majority of experts agree that a single mTBI is 
unlikely to result in long-term adverse outcomes,84 the effects of repetitive mild traumatic 
brain injury (rmTBI) remain a source of controversy. Recently, there has been concern in 
both the scientific and lay communities that rmTBI may be associated with increased risk 
of chronic neurologic and psychiatric symptoms, or neurodegenerative disease, including 
chronic traumatic encephalopathy (CTE). Symptoms attributed to rmTBI, including 
memory disturbances, insomnia, pain, and increased seizure susceptibility,79 are 
indicative of a shift in brain excitability. The evolution of these symptoms over time and 
the enduring nature of them in a significant portion of patients points to a biology that is 
slow developing and potentially durable. 
Traumatic brain injury (TBI) causes pathologically-enhanced brain excitability 
which may lead to epileptogenesis in both animal models51 and in humans.42 Post-
traumatic epilepsy (PTE) is the most common form of acquired epilepsy in young adults 
and accounts for 10-20% of all epilepsy cases.72 Notably, mTBI, with or without repeated 
injury, predisposes patients to epilepsy. In a large scale retrospective study, people who 
experienced mTBI were 2.2 times more likely to develop epilepsy when compared to 
individuals without history of mTBI.21 Susceptibility to seizures was found to be the 
highest in the first few years after injury and remained significantly elevated more than 
10 years later. Similar (2.3 times greater) risk of acquiring epilepsy after mTBI has also 
been found in other large retrospective studies.7,8 Figure 1 shows increased chance of 
	
2 
developing epilepsy over time as well as other comorbidities of injury. However, the 
biological mechanisms that definitively link rmTBI and epileptogenesis remains to be 
categorically elucidated.		
	
Figure 1 “Post-TBI morbidity connectome and timelines for morbidogenesis. Adapted 
from Pitkanen et al.101 (A) Post-TBI morbidity connectome summarizing different types 
of comorbidities, including epilepsy that can develop after TBI in humans. The blue lines 
link epilepsy to other morbidities described in animal models of PTE. (B) 
Epileptogenesis after severe TBI continues for up to 1 year. Motor, sensory, behavioral, 
and cognitive impairments are apparent within days after TBI. Importantly, spontaneous 
recovery is fastest during the first 1–3 months post-TBI. The y-axis shows the percentage 
of subjects with epilepsy over time (x-axis). (C) Like in experimental models, 
epileptogenesis has a substantially longer-lasting evolution time than the recovery of 
motor and cognitive functions in patients with TBI as well.” 
 
The increased risk of epilepsy following mTBI may be driven by injury-related 
changes in the excitatory-inhibitory (E/I) balance that are principally driven by the two 
major neurotransmitters in the brain, glutamate (Glu) and gamma aminobutyric acid 
(GABA). Changes in the levels of one or both of these neurotransmitters can shift the E/I 
balance. Notably, increasing extracellular Glu or decreasing GABA might lead to excess 
excitation and epileptogenesis.72 
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Loss of parvalbumin-expressing GABAergic interneurons (PVI) and cortical 
inhibition following severe TBI has recently been established in rats.51 Whether PVI loss 
is relevant to rmTBI has not been fully established, but may be critical for design of 
effective treatment after injury.92 Further, the mechanism by which PVI loss, E/I balance 
shift, and other components of the pathology occur after injury remains incompletely 
understood. In the severe TBI model, there is evidence of a progressive pathology, 51 and 
there is mounting evidence that a similar effect is seen even beginning in mild injuries.76 
This work aims to provide insight into the potential cellular and molecular 
mechanisms of shifted E/I balance, loss of cortical inhibitory tone, and epileptogenesis 
after mTBI and rmTBI. Understanding the underlying mechanisms that precipitate after 
injury will help identify novel therapeutic targets for post-traumatic epilepsy. The 
proposed progression from injury to PTE can be seen in Figure 2101. Current first line 
antiepileptic medications aim to prevent seizures from recurring, addressing only the 
symptoms of a damaged brain, plus all treatments are attributed with undesirable side 
effects. This strategy is essentially treating patients as if they already have the disease, 
not addressing the development of the disease state, which given the timeline is distinct 
from the initial injury. The rationale behind this study is that better drugs can be designed 
to prevent the development of disease if the mechanism of how the brain is changing can 
be established. Through extensive literature search, I hope to better elucidate the 
mechanisms that precipitate PTE to later guide the development of better pharmaceutical 


















Traumatic brain injury (TBI) is a major global health concern. Though there is a 
significant range in injuries that qualify as TBI, each have their own unique 
considerations to take when thinking about acute and long-term care and treatment. These 
injuries can range from mild to severe. Mild injuries, more commonly referred to as 
mTBI or concussions, are calculated to be as prevalent as between 2.5% and 18%100 -- 
meaning 2.5% to 18% of the global population has sustained at least one mTBI. This 
enormous range is due to multiple factors including under reporting of injury and 
differing clinical definitions and thresholds for injury worldwide. Using these numbers as 
bounds, there are somewhere between 195 million and 1.4 billion people that have had at 
least one concussion. Estimates of sport-related concussions are estimated between 1.6 
and 3.8 million annually in the United States alone.19 In a study of concussions sustained 
by athletes, 13.2% of injuries observed were not the athlete’s first.19 A significant portion 
of the population that sustains concussions are therefore likely to experience more than 
one in their lifetime.  
Mild TBI is broadly defined as an injury caused by mechanism of a direct blow to 
the head, or a transmitted blow to the body that causes sequential acceleration and 
deceleration of the brain, but one that does not leave any physical markers by magnetic 
resonance imaging (MRI), or other common gross inspection measures. Patients score 
between a 13-15 on the Glasgow coma scale (GCS) (see appendix), a common metric 
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used to determine the level of cognitive functioning after injury (normal healthy 
functioning patients will score a 15 on this scale). Symptoms after mTBI are generally 
categorized into four groups; somatic, cognitive, mood, and sleep.20 These categories all 
suggest a possible common denominator in altered cortical excitability. 
Major issues exist in the accurate tracking and reporting of mTBI. Due to its mild 
nature and lack of concrete definition and consensus of thresholds between grades of 
injury, it is likely that a large number of events go unreported, meaning total 
incidence/prevalence calculations are under-counting true burden. The nature of the 
spontaneous recovery has led to slow development of and limited options in medical 
interventions available and established as standard-of-care. Patients may never seek 
medical attention due to these significant limitations, ultimately resulting in under 
reporting. This under reporting likely skews the spontaneous recovery data as well - it is 
estimated that as many as half of the injuries that occur go unreported.20  
mTBI injuries are incredibly common, impacting contact sport athletes and 
military personnel as well as individuals involved in motor vehicle accidents the most 
frequently. Millions are affected every year, however the exact quantification of 
individuals effected is undercounted due to the intensity of the injury and current social 
thinking and behavior around the potential gravity of this type of injury. The precise 
definition and classification of this injury is currently defined more by what it is not than 
what it is, which makes the accurate and meaningful study of it through animal modeling 
difficult. This in turn prevents the social change in attitude needed to increase capture 
rates and develop more meaningful clinical research studies. 
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Additionally, making decisions regarding guidelines and public health policies is 
incredibly difficult if not impossible under the current available scientific data. The 
heterogeneity of the injury along with the issue of accurately tracking and collecting 
numbers and cases due to under reporting makes decision making and treatment 
designing an enormous challenge. There is a definitive need for both scientific data 
collection improvement as well as a shift in social perception in order to increase the 
quality of the data.81 These factors in combination result in the current state of the clinical 
reporting guidelines, which are intentionally loose and provide plenty of room for 
subjective bias and influence.84 
 
Symptoms associated with mTBI 
Metabolic 
Many of the symptoms of concussion can be linked to changes in cellular 
metabolism and dysregulation of mitochondrial function and imbalanced neurotransmitter 
(NT) levels resulting in a cellular energy crisis.44 Due to physical changes in cellular 
membrane integrity, changes in ionic gradients cause an increased demand for energy in 
the form of ATP. This causes hyper-glycolysis and a relative depletion of intracellular 
energy stores. Additionally, rising levels of intracellular Ca2+ cause mitochondria to 
sequester some of this excess load and results in the production of reactive oxygen 
species (ROS), increasing intracellular oxidative stress (Figure 3)44,46. The energy 
dysregulation in the brain after mTBI is great enough to alter total resting metabolic rate 
(RMR). The degree of this change is different between men and women and should be 
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considered accordingly if RMR is being used to assist in diagnosis or to determine 
resolution of symptoms.127 Fatigue is also a common symptom for those experiencing 
prolonged symptomatology after mTBI. This persistent fatigue has recently been 
attributed to neural and metabolic dysfunction.99  
 
Figure 3 The metabolic cascade after single and repeat concussions. (A) Upon 
impact, neuronal membranes are mechanically disrupted causing the indiscriminate 
release of neurotransmitters (glutamate) and neuronal depolarization. The activation of 
the post synaptic receptors causes an influx of excitatory amino acids (sodium and 
calcium) and efflux of potassium. The disruption of ionic equilibrium triggers activation 
of energy dependent pumps, thereby increasing energy demands of the cell and increases 
brain glucose uptake. The brain then enters a prolonged period of glucose metabolic 
depression, which may be a reflection of the brain's vulnerable state. (B) Illustration of 
the concept of metabolic vulnerability and how the interval between injuries can 
influence recovery.Adapted from Greco et al.46 (C) Neurometabolic cascade Adapted 
from Giza and Hovda44 
 
Neuro/Cognitive 
mTBI has also been associated with long term (late emerging) depression and 
general cognitive impairment, including issues with executive functioning. These 
symptoms speak to a decline in overall cognitive health late in life.24 The emergence of 




suggests a slow accumulation or progression of pathological changes that are yet to be 
explicitly identified pre-mortem (Figure 1)101.  
In a study of retired professional football players, the relationship between self-
reported history of concussion and diagnosis of depression revealed a dose response 
relationship between number of reported concussions and eventual diagnosis of 
depression within the 10 years of the study. Those players that reported no concussions 
had a 3% risk of depression diagnosis while the players that reported having 10 or more 
concussions were found to have a 26.8% risk.61 This further speaks to the lasting change 
and compound effect of repeat injuries. Patients that have been concussed also exhibit a 
long term increase in suicidality, three times that of the general population.41 These 
factors alone provide evidence of the gravity of neurocognitive changes pursuant to 
mTBI that warrant further investigation. 
 
Biologic Aging 
A deficiency in DNA-repair mechanisms has been found in concussed former-
athletes.14 This deficiency leads to increased levels of DNA damage, and the inability to 
repair the damage suggests a progressive buildup of genetic mistakes and therefore issues 
with protein translation. These issues in many cases were found to lead to neuronal 
senescence. Recently, an increasing body of work has been established investigating the 
long-term effects of repeated concussions in retired football players and military 
personnel. Findings of Chronic Traumatic Encephalopathy (CTE) reveal widespread Tau 
protein deposition, and atrophy of critical brain structures, similar to Alzheimer’s and 
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other neurodegenerative diseases. These changes thus far are only able to be confirmed 
post-mortem.14 The accumulation of misfolded proteins both within cells and in the 
extracellular space significantly alters function and can have a wide range of clinical 
manifestations if allowed to progress long enough. There is a serious need for novel 
therapies to prevent abnormal protein accumulation in this patient population.  
mTBI has been associated with sleep disturbances including probable rapid eye 
movement (REM) sleep behavior disorder (pRBD), a parasomnia associated with Lewy 
body deposition.2 Sleep disorders emerging earlier in life suggest cellular waste 
management systems that have been compromised. Over time this hypofunctional 
clearance may lead to accumulations of metabolites and cellular products further 
impairing other cellular functions. Sleep disorders may serve as biomarkers of overall 
neuronal health. Deficiencies in sleep should be addressed early to prevent long term 
progression to more serious neurological disease. 
 
Course of Recovery and Consequences of Repeated Injury 
Most patients suffering from symptoms of mTBI present early and report their 
symptoms resolving spontaneously between two weeks and three months after injury. 
However, some patients report a later onset of symptoms and ultimately 11.8% are still 
symptomatic after 3 months. This range of experiences further increases the difficulty in 
truly capturing mTBI incidence and speaks to the heterogeneity of injury and risk.7 
Patients that have suffered repeat concussions report worse symptom severity and longer 
duration of symptoms, suggesting a cumulative effect and lasting change after initial 
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insult.19 Patients who participate in sports also reported longer return-to-play times. It is 
important to note that both prior injury and the recency of the prior injury increases 
symptom severity and duration of symptoms independently. Each subsequent injury is 
worse, suggesting durable changes after each insult.38,46 Schilling et al. recently found 
that symptom profile and symptom severity both independently contribute to prolonged 
recovery time.111  
The current protocols on average suggest return to play is sufficiently safe after 
resolution of symptoms and on average, recoveries are about 10-14 days long. However, 
a study in 2020 found that less than 50% of patients are truly recovered by this time 
point.58 A large meta-analysis found that cognitive impairment was still present multiple 
months after injury in 50% of single mTBI patients, let alone those who have repeat 
injury.85  
Recently, it has been established that metabolic and neurovascular changes 
pursuant to injury can significantly outlast the physical symptoms of mTBI.57 Due to the 
heterogeneous nature of mTBI and the fact that some symptoms may resolve before the 
unseen metabolic changes have resolved suggest an increased window of risk beyond the 
resolution of physical symptoms. This variable window requires the guidelines that 
determine return to play timelines to be conservative.56 Additionally, to complicate the 
picture, exercise seems to increase both symptom resolution and patient quality of life, 
but each consecutive injury increases risk of long term impairment including, potentially, 
CTE.87 Balancing the risk of additional injury with increasing recovery time is a critical 
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consideration for designing return-to-play guidelines, especially since there is increased 
susceptibility to future injury after the initial insult. 
 
Effects by population 
There seem to be different effects and vulnerabilities of patients who suffer from 
symptoms of post-concussion syndrome when segregated by sex. Females are likely to 
experience a slightly different subset of symptoms when compared to their male 
counterparts. Men have been reported with more memory deficits, while women have 
reported more depressive symptoms. These findings have also been seen in animal 
studies.46 When age is taken into account for mTBI patients, older adults reported fewer 
symptoms, however the severity of the symptoms remain similar and the relationship 
between symptoms and loss of function remain constant across age groups.59 Children 
that experience prolonged symptoms are likely to have complex factors that increase their 
risk, including socioeconomic status (SES) and caregiver stress. The pronounced effect of 
social and environmental factors on outcome and recovery time adds an additional layer 
of complexity to the greater picture of mTBI. These factors may also increase the risk of 
other issues that may present themselves later such as PTE.105  
mTBI has been associated with an increase in vulnerability to post-traumatic 
seizures and subsequently post traumatic epilepsy (PTE). This susceptibility has been 
shown to be increased in children with multiple mTBIs.52 Although the work done by 
Kuhl et al. showed a low risk for developing PTE after mTBI, the risk was still elevated. 
This finding was also in the context of a 3.3 year follow up, which may not be long 
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enough to truly capture the full effect.65 Teasing out the relationship between mTBI and 
PTE is difficult due to the direction of causality. Are mTBI patients prone to PTE or are 
latent epilepsy patients more prone to mTBI, and therefor any pursuant injury may be 
attributed as reverse causality? Sufficiently controlling for the time between diagnoses 
should mitigate most of the potential conflation of directionality. 
 
Post traumatic Epilepsy (PTE) 
Epilepsy is often thought of as an imbalance between the two major forces in the 
brain, excitation and inhibition. This is commonly referred to as the Excitation/Inhibition 
balance (E/I balance). If some change occurs to the brain to shift this equilibrium towards 
excitation, the result is a seizure. From this broad lens two alterations will increase the 
likelihood of seizure generation: an increase in excitation, or a decrease in inhibition. 
Either will cause a net gain in excitation, and unchecked excitation will feed forward and 
likely culminate in a seizure if not widespread cellular damage. 
It is estimated that 500,000 TBIs lead to hospitalization each year in the United 
States. Severe TBI has been calculated to increase risk of developing PTE from 26-53% 
over incidence in the general population. If only current epilepsy cases are considered, 
5% of total cases are the direct result of TBI. Importantly, PTE accounts for 20% of total 
symptomatic epilepsy cases.9 The latest global lifetime prevalence of epilepsy is 7.60 per 
1,000 person years, with an incidence rate of 61.44 per 100,000 person years. The 
prevalence does not differ by age or sex.40 Drug resistant epilepsy is a significant 
proportion of total epilepsy cases, about 33% of pediatric cases and between 30-40% in 
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adults.55 Cases that cannot be effectively treated by current pharmaceuticals are referred 
to as intractable or refractory. This proportion of patients with refractory epilepsy 
dramatically increases the economic burden of the disease and dramatically decreases the 
quality of life for patients.39 
The cascades of epileptogenesis occur at different time scales than the resolution 
of symptoms from standard TBIs. These cascades, though not fully characterized, likely 
operate on the order of years instead of weeks or months. The 30-year cumulative 
incidence of mild TBI has been calculated at 2.1% - three times the incidence of epilepsy 
in the general population. Once a TBI patient of any severity has experienced their first 
seizure, there is an 86% chance that they develop a second.101 It is not only possible but 
also likely that the timelines and cascades of the differing severities of TBI will also 
differ. Further research of these timelines and cascades will ideally lead to the discovery 
of druggable targets to better treat and potentially prophylax against late onset PTE from 
mTBI. 
As it stands, all treatment modalities are aimed at preventing seizures from 
continuing to occur. Effective treatment of the development of epilepsy, epileptogenesis, 
remains elusive. Valproic acid (VPA) is the only AED being tested as an 
antiepileptogenic with limited success.9 The challenge of designing a treatment, 
pharmaceutical or otherwise, lies in the assessment of outcomes. If all injured patients do 
not go on to develop epilepsy, a significant reduction in incidence needs to be seen likely 




Epidemiology of mTBI related PTE 
There is significant evidence that mTBI increases risk for developing PTE in the 
literature. Below are the summaries of the most relevant experiments on this work, 
including their strengths and weaknesses.  
Annegers et al. were the first to attempt to differentiate the effects of PTE from 
varying levels of severity of injury. The authors classified injuries into mild, moderate, 
and severe categories, defining mild injury by Loss of Consciousness (LOC) of less than 
thirty minutes.5 This study excluded patients if they received a second TBI. Under these 
conditions, they found a 1.5% relative risk in mTBI population (i.e. patients that had been 
injured were 1.5% more likely to develop epilepsy compared to uninjured age matched 
patients). They established a 3.1 incidence ratio -- for every ten healthy people that 
developed epilepsy, thirty one injured people would develop PTE. This was further 
characterized by an incidence ratio of 2.1 when exclusively Post Traumatic Amnesia 
(PTA) patients were included, and an incidence ratio of 2.5 with exclusively LOC. The 
authors report a limitation as their standard control population was restricted to one 
hospital in Minnesota and therefor may not be fully representative of 
national/international rates. 
Christensen et al. in 2009 published their study using the Danish registry system 
to orchestrate a large scale population study of 1.6 million people from 1977-2002.21 
They also categorized injuries into mild, severe, and cranial fracture using the 
International Classification of Disease or ICD 10 codes to track patients. All patients in 
this study were hospitalized and on average had six-month interval follow-ups. Mild 
	
16 
injury was defined as LOC of less than thirty minutes and a GCS of thirteen or greater. 
Christensen et al. report a relative risk of 2.2 for people with mTBI to develop PTE. 
Interestingly, they found females more likely than males to develop PTE, with a relative 
risk of 2.5 compared to 2.0. Limitations on this study include slow diagnoses potentially 
concealing reverse causality, i.e., a seizure causing LOC and mTBI. However, this was 
attempted to be corrected by excluding diagnoses within 6 weeks of TBI. 
In their study of Stockholm residents from 1980-2008, Mahler et al. defined mild 
injury as LOC of less than thirty minutes and a GCS of greater than thirteen (comparable 
to Annegers definition). They report the Relative Risk, which they equate to the Odds 
Ratio. From here, they calculate the Attributable fraction (AF) which is (relative risk -
1/relative risk) x prevalence among TBI. This yielded AF of mTBI of 1.8 and 
interestingly an AF of severe TBI of 1.9, suggesting that mild and severe injuries likely 
contribute equally to disease burden. Though rates are higher in severe injury, there are 
significantly more mTBIs, which result in a similar total burden. They found a similar 
female trend as Christensen, where there is a slightly higher incidence in women. 
Importantly, they found that symptoms/diagnosis of PTE take longer to appear in mild 
cases.77 
Wenneberg et al. produced a study in 2018 using the most uniform control 
population of the studies investigated. They included 330 patients, some with multiple 
concussions. An average 7 year follow up with 87% of patients followed for longer than 
6 months. They report no increased incidence 5-10 years out from mild injury. The use of 
ICD 10 codes can be limiting, and they report being underpowered to show 2-fold 
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difference, needing 380 patients by power analysis. The discussion of this paper 
highlighted the potential for unmasking latent epileptic tendencies with injury. However, 
even if this is the case, the increase in number of people with active Epilepsy would 
increase, ultimately supporting the thesis of this argument. 128 
Frey et al. in 2003 reviewed the status of PTE. They looked at early seizures 
(<7d) as distinct from late seizures in which “early” included Status Epilepticus (SE), a 
serious condition in which seizures are incredibly frequent and uncontrolled. In their 
review, they also compared civilian populations to military personnel, as well as pediatric 
patients to adult patients. They report a Standard Incidence Ratio of 1.5 for patients 18 
years and older compared to a ratio of 5.9 in the pediatric population, suggesting a greatly 
increased susceptibility to seizures in children exposed to injury.42 
Hung et al. review the incidence of PTE in the pediatric population (<18 years 
old), in which they review 25 eligible articles. They investigated various deficits after 
injury, including epilepsy, and reports included followed from less than one month after 
injury to greater than three months. They report “of the published research there is little 
evidence of long-term effects the majority of patients fully recover.” However, they 
acknowledge reports of epilepsy is a simplistic conclusion when investigating this 
population.53 
Keret et al. investigated 191 patients, all children (<18 years old), admitted to a 
singular medical center between 2007-2009. The majority of the population sampled was 
between the ages of 1-4 years (>33%). The follow up time averaged 7 years. They used a 
definition of mTBI based on GCS similar to other studies considered here, but differed in 
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that most had a linear skull fracture. They found a mean onset time of epilepsy of 3 years 
in 3.1% rate of incidence in children admitted for mTBI.60 The inclusion of linear skull 
fractures may change the type of injury investigated here, but not all patients suffered this 
type of injury and they all fell in the same GCS range as other investigations.  
In summary, significant ranges in the methods and definitions of “mild” TBI, each 
with their own limitations, make drawing cohesive conclusions from published medical 
literature difficult. However, despite this limitation, strong trends seem to persist. 
Relative risk scores between 1.4 and 2.2 percent have been established across multiple 
long-term studies across decades of research and millions of person years. The largest 
population studies all use ICD 10 codes and only count hospitalized patients, but follow 
over 1 million patients for long periods of time. These studies show relative risk rates of 
1.5-2.2, and Incidence Rates of 3.1. The only strictly controlled population to date has 
shown no increased incidence; however, there were significant limitations in adequately 
assessing whether this relationship definitively persists. This study did not follow patients 
longer than 3 months and the epilepsy measure was a simple yes or no epilepsy diagnosis 
within that time.  
The incidence of epilepsy in the general population is 0.7%, less than one in every 
100. Even if these large population-based studies are overestimating because of ICD 10 
inclusion criteria, the incidence rate of 1.4 and 2.2 are a 2-fold and 3-fold change over 
global incidence. Smaller change may still be relevant, as millions are affected by mTBI 
annually. As of the writing of this manuscript, there is limited to no information on 
repeated mTBI as a distinct pathology from Chronic Traumatic Encephalopathy. 
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Calculations of Burden 
The global prevalence of concussion is reported between 2.5% and 18%. This 
enormous range is due to multiple factors including under reporting and differing 
definitions worldwide. Using these numbers as bounds there is somewhere between 195 
million people and 1.4 billion people that have had at least one concussion. The age 
adjusted prevalence of Epilepsy is reported at 0.73. If the global population is 7.8 billion 
people, then by this calculation there are 56.7 million people in the world with epilepsy. 
The World Health Organization (WHO) estimated in 2001 that there were about 50 
million people in the world with epilepsy. If the estimates by Mahler77, Annegers5, 
Christensen21, Frey42 and Keret60 are correct, and the prevalence of concussed individuals 
developing a concussion is between 1.4 and 2.1, this is a 2x and 3x increase over the 
general population’s risk to develop a concussion. Though the overall percent appears 
low, when factoring in the prevalence of mTBI (195 million to 1.4 billion), these 
numbers quickly become significant. For instance, 1.4% of 195 million people is 2.8 
million people, while 1.4% of 1.4 billion is 19.7 million people. If the higher incidence 
rates are used, concussion induced epilepsy cases number between 4.1 million and 29 
million. If appropriate treatment and prophylaxis modalities were established to return the 
prevalence of epilepsy back to the average population i.e., the excess burden was 
removed, between 1.4 million and 9.8 million excess cases at 1.4% and between 2.7 
million and 19.5 million cases in excess of global prevalence. The range of 1.4 million to 
19.5 million may seem suspicious, but ultimately any change to current standard practices 
will affect over a million if not millions of people worldwide. It is also important to 
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highlight once again that 30-40% of all epilepsy cases are not adequately controlled by 
medications and deemed intractable. So of those excess, one third or more will not be 
able to have their disease effectively managed by current modalities. This further 
highlights the need for effective treatments to prevent the progression of disease that 
effects so many. Any improvement would have global impact. 
 
Biological Cascade 
Considerations and Limitations of Animal Models  
Animal studies provide a unique window into disease progression with markers of 
the biological underpinnings otherwise inaccessible in human populations and ideally, all 
animal research is translatable or at least can be used to inform clinical experiments. 
Ultimately, the goal is to understand the disease in humans enough to effectively treat 
and improve quality of life of patients.  
The number of animal models of mTBI have been steadily increasing over time. 
These methods include weight drop models89, controlled cortical impact models78, and 
even the Closed Head Injury Model of Engineered Rotational Acceleration also known as 
CHIMERA126, which focuses on the acceleration and deceleration forces that cause 
axonal shearing (strain on the axons that damage the myelin and membrane). Each of 
these models have proven to have their own strengths and weaknesses and the choice of 
model should be taken into account when interpreting the results.12 Importantly, the range 
of models and the medical community’s lack of uniformity in injury definition, has led to 
varied and difficult to interpret results. There seem to be as many types of injury models 
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as there are injury paradigms (i.e. number and frequency of injuries) and follow up times 
adding another variable to an already complex picture from a literature stand point.13 As 
one might expect, models that compare single versus repeat injuries show a worsening of 
symptoms and a prolonged recovery time in repeatedly injured animals.  
It has long been established in animal models that severe TBI leads to PTE in 
25+% percent of injured animals with various methods. Successful models of PTE in 
animals often are defined by their ability to produce spontaneous seizures.25 These 
numbers are even greater when investigated by long term EEG.4 The use of EEG is the 
gold standard for assessing seizure frequency as electrographic seizures may appear 
significantly more frequently than clinical seizures and may be as important for 
translational purposes. Electrographic seizures are characterized in part by frequent 
spikes of electrical activity that have very characteristic presentation. Another difficulty 
in studying long term epileptogenesis in mice is that all mice at baseline have some small 
amount of pre-epileptic discharges, commonly known as spikes. Each mouse strain has a 
different baseline of spiking activity that needs to be taken into consideration when 
evaluating PTE in mouse models.104 Current animal models and published works have 
not passed 6 months in follow up time. If true long term emergence of PTE after mTBI is 
to be understood this needs to improve.72 
It is well established that TBI causes alterations in the E/I balance skewing the 
balance towards excitation, ultimately leading to differences in cortical excitability and 
predispose brains for epileptogenesis.47 It is important to note that some genetic 
epilepsies occur from mutations in transmembrane channels. These channelopathies can 
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result in alterations in the gradients of ions across cell membranes and lead to hyper or 
hypo excitability.122 This speaks to the scope of the lens of looking at E/I balance. Even 
events on the ion scale may impact this delicate balance. Ultimately the E/I balance is the 
metric that will be used to assess the impact of smaller perturbations in cellular 
functioning.  
 
Structural changes after mTBI 
The acceleration and deceleration of the brain causes strain on individual cells, 
producing shearing forces that change membrane permeability and lead to a whole host 
of issues. Neurons, glia and vasculature are all affected by these forces and the 
consequences are widespread though each seem to recover on their own timescale. 
Vascular damage can lead to compromises in the blood brain barrier (BBB) which 
under normal circumstances forms a protective structure that tightly regulates what 
materials are allowed to enter the brain. Damage to this barrier allows metabolites solutes 
and even cells which under normal circumstances would not have access to neural tissue 
to enter. Foreign substances can cause widespread inflammation. Though the damage is 
not on the scale of a hemorrhage or stroke, small but widespread incidences that mimic 
these events can still wreak havoc on the brain resulting in the various post-concussion 
syndrome (PCS) symptoms discussed earlier. In an animal model of rmTBI, Adams et al. 
found decreased cerebral blood flow and vascular reactivity two weeks out from the final 
injury.1 These vascular issues have been shown to outlast the resolution of many of the 
behavioral symptoms associated with PCS. 
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Axons are selectively susceptible to shearing forces associated with mTBI. White 
matter injury from mTBI is associated with behavior deficits over two months after injury 
suggesting involvement of dysfunctional oligodendrocytes.86 The upregulation of 
transcription of the inflammatory marker Tumor Necrosis Factor Alpha (TNF-⍺) has 
been found alongside significant microgliosis in a model of repeated mTBI. These 
findings are accompanied by microstructural damage to the architecture of the brain 
detectable by Diffusion Tensor Imaging (DTI).107 Wide spread damage associated with 
this diffuse injury includes vascular damage that leads to inflammation and an immune 
response as well as structural damage to white matter tracts slowing the conduction of 
information within the brain. However, it is important to note that although the injury is 
considered to be diffuse and by definition not localized, this does not mean that certain 
areas and structure are not more susceptible to damage. In fact, due to the complex 
architecture constructed by various cell and tissue types, the presence of the ventricles, 
and the extracellular matrices that intertwine and interact to construct the organ that is the 
brain, it is almost guaranteed that as research advances, we will find different structures 
with dramatically different injuries. 
 
Metabolic and oxidative stress 
Metabolic disfunction is a long-lasting effect of mTBI. Signs of mitochondrial 
dysfunction, abnormal vascular perfusion and decreased neuronal ATP output are still 
present 1 month after injury in animals. Mitochondrial dysfunction points to a continued 
production of ROS and increased burden of oxidative stress. When the major antioxidant 
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of the brain, glutathione, was assessed in rmTBI injured animals, the ratio of oxidized to 
reduced Glutathione (GSH/GSSG) exhibited a steady decrease suggesting worsening 
oxidative stress conditions from 1 week after injury to 6 weeks after injury.76 This 
corroborates the human data and points to the use of Magnetic Resonance Spectroscopy 
(MRS) to identify biomarkers using metabolites of homeostatic processes to assess the 
condition of the brain after injury.75 
 
E/I balance Direct Implications 
Excitatory tone [Glu] 
Glutamate (Glu) is the primary excitatory neurotransmitter, and when referencing 
the E/I balance, Glu is essentially synonymous with E. The Glu dynamic within the brain 
effectively regulates neuronal firing. The frequency and duration of firing patterns 
influence larger functions such as neural plasticity and long-term potentiation and 
memory. Tightly regulated control of this potent excitatory substance in the extracellular 
space is crucial to appropriate functioning. Understanding the role of glutamate transport 
from the extracellular space back into the intracellular space in normal brain function is 
critical to understanding pathological effects of disease that effect the primary excitatory 
neurotransmitter. The primary Glu transporter in humans is the Excitatory Amino Acid 
Transporter 2 or EAAT2. Its analogue in mice is Glu transporter-1 (GLT-1). This critical 
protein has been reported to account for 1% of total brain protein and is the only way that 
Glu is removed from the synapse.26 There is no other way to inactivate the action-
potential leaving areas deficient in GLT-1 acutely sensitive to excess excitation and 
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feedforward excitotoxicity. Uptake of Glu follows the Na+ gradient, therefore 
perturbations in these can result in lower transport efficacy. Both neurons and glial cells 
express Glu transporters, though the function of neuronal synaptic functionality has been 
better characterized in the literature thus far. GLT-1 is so integral to brain function that a 
full knock out of this transporter’s gene is lethal in mice by 4 weeks of age. Interestingly, 
a knock down model in which 50% of protein is expressed shows no phenotype.27 So 
clearly there is an acceptable range of expression and likely that expression is plastic 
throughout life. GLT-1 is mostly expressed in astrocytes, however neuronal expression at 
synaptic terminals accounts for 5-10% of total GLT-1 expression and is a key player in 
the homeostasis of neuronal energy metabolism.88 
The glutamate-glutamine cycle is another important aspect of glutamate 
metabolism that may be deranged in epileptogenic injuries. Decreases in the enzyme 
glutamine synthetase reduce the conversion of Glu to Gln and have been shown in 
models of epilepsy due to the resulting excess Glu burden, system wide.37 
 
Inhibitory tone [GABA] 
Gamma amino butyric acid (GABA) is the major inhibitory neurotransmitter in 
the brain and when referencing E/I is essentially synonymous with I. There are three 
major types of GABAergic neurons in the brain; parvalbumin positive inhibitory 
interneurons (PVI), Somatostatin positive neurons (SOM) and 5-HT3a positive neurons. 




PVI are unique in that they can fire at high frequencies due to their parvalbumin 
(PV) content. Parvalbumin is a Ca2+ chelating protein which allows it to function at much 
higher intracellular Ca2+ levels than other cells. Normally Ca2+ is a tightly regulated ion 
because it is associated with many intracellular pathways in the growth cycle and, 
importantly, apoptosis. High intracellular Ca2+ is normally deadly to cells. However, Ca2+ 
is also an integral ion to neurotransmission. In order to release neurotransmitter (NT) into 
the synapse a neuron must use Ca2+ to facilitate the fusion of the vesicle containing NT 
with the cell membrane. The parvalbumin content allows these inhibitory interneurons to 
fire at an incredibly high rate, effectively regulating the transmission of many other cells 
simultaneously. In this way, PVI coordinate and synchronize larger-scale brain signaling. 
Normal PVI function is critical to mechanisms of learning and memory.34 They have also 
been shown to be responsible for generating the gamma band (30-80 Hz) on EEG17. 
Glutamatergic Pyramidal cells are not able to fire as fast and have been shown to 
contribute mostly to lower frequency bands.17 Interestingly, the influence of 
glutamatergic NMDA receptor mediated activation of PVI has been shown to be critical 
in establishing the normal gamma band, and in the expression of PV itself.18 
Optogenetic manipulation of PV cells drives gamma expression cementing the 
relationship between the two.117 Modulation of gamma is crucial for the enhancement of 
signal transmission. The greater signal function within the brain is larger than the sum of 
go-and-stop signals. It is the result of fluid coordination of these two, in a delicate 
balance that is always in flux. Any perturbations to the system quickly lead to large scale 
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dysfunction. NMDA hypofunction and decreased GSH synthesis capacity have been 
shown to decrease PV expression within PVI and reduce gamma band output.50 
Prolonged oxidative stress has been shown to decrease parvalbumin expression in 
PVI and is also associated with a proportional drop in gamma power.102 Loss of PV 
expression leads to asynchronous GABA release and the improper signaling resulting in 
poor cortical coordination.125 PV cell health is critical for maintaining adequate 
GABAergic inhibitory tone in the brain. 
Dynamic PV expression within PVI has been documented in a model of rmTBI. 
Initially, under conditions of high extracellular glutamate, PV expression was enhanced 
within PVI suggesting a compensatory mechanism. However, this seemed to be fleeting 
because by six weeks after injury, the PV expression had dropped 60% and a 
corresponding drop in gamma power by EEG and extracellular GABA concentration by 
microdialysis was reported.76 This dynamic expression is important to keep in mind when 
designing treatments to mitigate the progression of the disease. Knowing how cascades 
progress is critical to the success of future treatments  
 
PNN 
The Peri-Neuronal Net (PNN) is a specialized extracellular matrix that 
preferentially surrounds PVI. These nets are complex dynamic structures that are 
comprised of varied components including hyaluronan, chondroitin sulfate proteoglycans 
(CSPGs), and a multitude of glycoproteins. Two critical components of a healthy 
functional net are the CSPGs Aggrecan and Brevican.118 Components of PNN, namely 
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Brevican, have also been shown to coordinate and organize components of the cellular 
membrane ultimately influencing cellular function and plasticity. The compound Otx2 is 
shuttled by PNN in PV positive inhibitory interneurons to open and close critical periods 
of plasticity. Without their PNN, Otx2 is ineffectively coordinated and this modulation of 
plasticity is lost leaving PVI highly susceptible to influence from their environment.10 
Otx2 is generated in the choroid plexus that lines the ventricles of the brain. It is then 
shuttled through the PNN to PVI to influence plasticity and maturity. 
The PNN has been shown to defend against iron induced neurodegeneration.119   
PNN have been shown to protect PVI from oxidative stress insult, however they are also 
sensitive to damage from reactive oxygen species as well.15 In a model of rmTBI, PNN 
was shown to be degraded under oxidative conditions allowing PVI to change their  
PV expression.76 However, once the PNN integrity returned, PV expression was much 
less plastic. With recent gains in scientific understanding of the role PNNs play in a 
healthy brain and the nature of their dynamics, PNNs should be considered as a valuable 
target for pharmaceutical intervention.121 
  
Gliosis 
Astrocytes have been shown to increase their expression of glial fibrillary acidic 
protein (GFAP) in severe TBI models in a process known as reactive astrocytosis. This 
has also been found in models of rmTBI.79 Increased GFAP expression is associated with 
the reduction of GLT-1 expressed by these astrocytes, which would increase 
concentrations of extracellular Glu and shift E/I balance towards excitation. 
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 However, there have been multiple reports of decreased GFAP expression after 
mTBI and rmTBI. In these cases, the downregulation of GFAP is also accompanied by 
the downregulation of other proteins responsible for homeostatic metabolism and 
astrocytic decoupling from synapses. These drop-outs of GFAP have been associated 
with worse behavioral outcomes and even PTE.28 A repetitive diffuse TBI model 
inducing three injuries in the same day has been shown to produce PTE by long-term 
EEG monitoring.113 This model has also been shown to produce interesting astroglial 
behavior, in which homeostatic proteins including GLT-1 and GFAP are down regulated 
and astrocytes appear to be decoupled, lacking their characteristic gap junctions (which 
are crucial to their function as reservoirs of extra-neuronal proteins and metabolites).114 
Another protein of interest is xCT – the cysteine Glu exchanger found in 
astrocytes around vasculature and lining the ventricles. Cysteine is required for the 
production of glutathione, the brains primary mechanism for dealing with oxidative 
stress. This transmembrane protein pulls cysteine into the cell in exchange for Glu, thus 
increasing extracellular Glu concentrations around these astrocytes, though much of this 
increase is buffered by the GLT-1 content on the astrocyte.96 Some of this excess may be 
mitigated by GLT-1. However, the proximity to susceptible areas including the choroid 
plexus may increase the strain on this system. Increased demand for GSH will come at 
the expense of increase extracellular Glu. 
Severe astrogliosis has been shown to be sufficient to induce epileptogenesis. 
Reactive astrocytosis is associated with decreased extracellular Glu clearance by reduced 
GLT-1 expression. The Cl- gradient has also been shown to be disrupted by the 
	
30 
dysfunction of the Cl- transporters KCC1 and NKCC2.106 The Cl- gradient is responsible 
for maintaining the inhibitory effects of GABA – the primary mechanism for inhibition. 
Lessening the effects of GABA would result in increasing E/I balance. 
Astrocytes are not the only cell type involved in the glial response to mTBI, 
microglia also play an important role. Microglial activation is associated with widespread 
neuroinflammation and the presence of ROS, and prolonged activation can lead to 
neuronal death, as is the case in many neurodegenerative diseases. In a model of rmTBI, 
mice were shown to have deficits in memory tasks, along with the presence of both 
astrocytosis and microgliosis three months after the final injury when compared to sham-
injured animals.79 
Mountney et al. report this enhancement of GFAP response, neuroinflammation, 
and alterations in gait. They also report white matter thinning in the repeatedly injured 
animals. Importantly, the behavioral symptoms resolve before the metabolic and cellular 
symptoms. As the biological underpinnings of this injury are better understood, the 
timeline of onset and resolution of each pathway needs to be taken into account when 
designing interventions, as some may be appropriate at one point along the course of 
injury but not at others. 
 
Additional considerations 
When the effects of rmTBI were investigated in both adolescent and adult mice, 
interesting differences emerged. The injured pediatric mice performed worse on spatial 
memory tasks than adults, but both injured groups were significantly worse than sham. 
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Additionally, an increased microglial response was found in younger mice but not 
adults.80 
In severe TBI, non-invasive neurophysiological markers of cortical inhibition loss 
track along with the progression of PVI loss and PNN injury.51 Using PV and PNN health 
as a proxy for overall function and health of tissue after injury is valid. 
 
Clinical Correlations 
Status of research and considerations 
A major hinderance in the accurate and meaningful progress of identifying and 
successfully treating mTBI is the lack of consensus among physicians and scientists 
about what defines an mTBI, what is a concussive injury verses a sub-concussive injury, 
and how is it best determined to differentiate between disease states. This lack of 
consensus has led to a burgeoning need for biomarkers and protocols for imaging 
techniques to establish a standard of care above the minimal interventions being given at 
this point in time.8 Establishing studies that examine chronic longitudinal follow up, 
especially for populations of high risk individuals, including American football players 
and military personnel, is critical to the advancement of knowledge and design of 
treatments for this injury.11 It is well established at this point mTBI is a constantly 
evolving process which necessitates that the timing of intervention will be nuanced and 
critical to successful outcomes.97  
Technology and assessment tools continue to improve, however there has been a 
lag in meaningful ways to apply these new technologies to address the disparities in 
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diagnostics and assessments in the mTBI and rmTBI population. Electroencephalography 
(EEG) is an incredibly powerful technique of assessing the electrical activity in the brain 
in real time. Novel methods of analysis are being developed to better tease out symptom 
severity and degree of recovery after mTBI.16 
Using tools such as accelerometers to precisely measure the exact biomechanical 
forces that induce (or fail to induce) certain mTBI injuries may be helpful for at-risk 
populations such as American football players and military personnel, where these 
measurements can be taken inside helmets or other gear worn by individuals. In addition 
to these measurements’ correlation with Magnetic Resonance Imaging (MRI) and 
(Diffusion Tensor Imaging) DTI, measures can relate forces to physical outcomes 
injuries. Impact velocity, peak linear and peak rotational acceleration, maximum 
principal strain, cumulative strain damage measure, and strain rate, are just a few 
examples of these measurments.23 
The use of any other these whole brain imaging techniques may also elucidate 
regional susceptibility of the brain to this injury that is commonly thought of as diffuse. 
The whole brain is affected by the injuring forces and thus, global disturbances may be 
seen, but the brain is by no means a uniform structure. It has an incredibly complex 
architecture which may leave certain areas more prone to injury. These regions of interest 
should be identified to better narrow the search for important biomarkers of disease.29 
Often the scale of injuries seen are too small to be detected by current imaging 
techniques. Though technology is advancing, no sufficient analysis technique has been 
widely approved or established to this date (Dec 2020).54 It is crucial that the medical 
	
33 
community continues to assess what imaging modalities and analytical techniques are the 
most appropriate and reliable in the diagnosis and design of possible treatment of patients 
with mTBI.116 
 
Structural imaging methods 
The use of MRI techniques to assess various structural injury markers is growing 
in popularity and power within the mTBI population. Recently, DTI, a technique that 
assesses the diffusional ability of water within cells, has been used to quantitatively 
assess the structural integrity of brain cells. In patients acutely recovering from TBI, an 
increase in the fractional anisotropy (FA) measure suggests a more permeable cell 
membrane, especially prominent at the interface between grey and white matter. These 
findings are joined by the identification of microhemorrhages throughout the brain.48 
Iron-mediated oxidative stress has recently be implicated in mTBI outcomes94 likely 
stemming from microhemorrhages.94 DTI can be used to assess brain symmetry as well 
as the integrity of the architecture. Substantial differences in symmetry in mTBI patients 
using this method have emerged suggesting that certain regions of interest may be more 
susceptible to injury.82 Selectively checking the integrity of these regions of interest may 
make identifying mTBI quicker than traditional methods. The identification of these 
regions also may lead to better targeted treatment options. 
The use of accelerometers to accurately calculate biomechanical forces that the 
brain may be subject to in mTBI is critical to establish threshold of injury. This combined 
with advances in imaging will greatly increase the diagnostic accuracy of mTBI in the 
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future.93 Studies conducted using helmet-mounted accelerometers suggest that American 
football players receive on the order of hundreds if not over one thousand sub-concussive 
hits in a single season. How many seasons do these athletes play in a lifetime? Frequency 
and intensity of impacts were correlated with fMRI deficits in connectivity and 
neuropsychological deficits by a series of batteries.6 This brings up the issue of repeated 
sub-concussive hits. Functional MRI (fMRI) is an imaging method that quantifies the 
metabolism of oxygen in both spatially and temporally quantifiable measure known as 
the BOLD signal. Due to its temporal component, it can be used to assess the 
connectivity and communication between separate brain regions. Lemme et al. have 
shown a pronounced decrease in resting state functional connectivity between concussed 
individuals and healthy controls. Concussed individuals who are currently experiencing 
post-concussion symptoms showed further decreased connectivity significantly more than 
their asymptomatic counterparts.68 
The development of an MRI algorithm that combines data from multiple types of 
scans, including MRI DTI and fMRI, has been reasonably successful in predicting 
outcomes and prolonged symptoms in patients with mTBI.73 
 
Blood Biomarkers 
Recently, McCrea et al. published an assessment of blood biomarkers in NCAA 
athletes throughout their season -- before play began (i.e. before concussive injury), 
acutely after their injury, 24-48 hours after injury, asymptomatic 7 days after return to 
play, and 6 months after injury. Increased GFAP and ubiquitin C-terminal hydrolase-L1 
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(UCH-L1) were elevated at the acute time point, but returned to normal by the time 
players were asymptomatic. Those with worse injuries, such as lost consciousness or 
reported post-concussive amnesia, displayed values that remained above their baseline 
levels even after return to play.83 
It is well documented that levels of VEGF and cytokines IL-6, IL-10, and TNF-a, 
can be used as biomarkers for moderate and severe TBI, but their use in mTBI is more 
nuanced. Thus far, these levels have only been able to predict the likelihood of MRI or 
CT findings, which under most definitions may not actually qualify as mTBI.36 This 
further speaks to the issue with the lack of cohesive diagnostic criteria and imprecise 
language used in this field, and an injury state that is defined more by what it is not than 
what it is. 
Differences in circulating Interleukin-6, a key cytokine and one of many 
inflammation pathways, was found in patients with recurring mTBI, but not their first 
insult. This suggests that there is an ongoing inflammatory response in subsequent 
injuries that make pathology distinct from the first mTBI.33 
 
MRS 
Severe TBI has been associated with hypometabolic rates in the thalamus by 
Positron Emission Tomography (PET).74 However, the use of PET involves the 
administration of radioactive substances to identify various targets. This is not without its 
own inherent risks, especially if designing a longitudinal study with multiple exposures to 
determine the trajectory of the cascade. For a mild injury with unknown vascular health, 
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that risk may not be worth the information gained. In an attempt to mitigate that risk but 
access similar information, research has looked to other methods. 
Magnetic Resonance Spectroscopy (MRS) is a powerful tool that can be used to 
determine levels of specific compounds in localized areas of the brain. It is noninvasive 
and can be done repeatedly throughout the course of recovery without unnecessary risk to 
the patient. One important relationship is the N-Acetyl aspartul-glutamate (NAAG) 
relationship to N-acetyl aspartate (NAA). When investigating the levels of these two 
prominent signals in mTBI brains, opposing changes in this ratio happened in grey matter 
compared to white matter, suggesting differing injury states within these broad categories 
of tissue. Notably, the decrease in NAAG in white matter suggests a lack of activity at the 
mGluR3 receptor, activity of which may confer neuroprotection.91 The decrease of this 
signal may be able to be supplemented through therapeutics and will likely be tested in 
the near future. Decreased NAA and tNAA+NAAG within ten hours of injury is 
associated with increase Glu production and failing oligodendrocyte health.124 
Veerameethu et al. in their 2018 paper captured the most acute biomarker readings of its 
kind and speak to a unique state of the brain after injury. Using MRS, Davits et al. found 
reduction in several markers including NAA, creatine, choline and myoinositol, although 
none of these reductions was significant. It was determined that there was diffuse axonal 
damage and regional deficits that could have likely been better distinguished by using a 
stronger magnet to achieve higher resolution.29 
1H+ MRS in the primary motor cortex (M1) and the Dorsolateral prefrontal cortex 
(DLPFC) assessed at 72 hours 2 weeks and 2 months after injury, revealed decreased 
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glutamate at 72 hours decreased GABA at 72 hours and 2 weeks and an increased 
Glu/GABA ratio at 2 weeks in Dorsolateral prefrontal cortex (DLPFC).129 The DLPFC 
dysfunction is also associated with depressive symptoms which have been well described 
in this patient population. This mirrors MacMullin et al.’s finding in mice and also 
furthers the theory of region-specific response to injury. 
 
TMS 
Transcranial Magnetic Stimulation (TMS) is also a powerful technique to 
noninvasively but directly assess the functional capacity and state of regions of the brain 
and spinal cord. Basic functional parameters can be assessed through various stimulation 
methods such as intracortical excitation, intracortical inhibition, input and output 
excitability. Common stimulation parameters and metrics assessed include; resting motor 
threshold (RMT), cortical silent period (CSP), Long interval cortical inhibition (LICI), 
short interval cortical inhibition (SICI), Intracortical facilitation (ICF), and short 
Intracortical facilitation (sICF). Resting motor threshold is the least amount of energy 
required to elicit a response from a stimulus, and is a relative measure of brain 
excitability. The CSP is the duration between the stimulus and the return of baseline 
activity, which is interpreted as a measure of cortical inhibitory tone -- the longer the CSP 
the greater the inhibitory tone. LICI is a pair of pulses used to measure the GABAB 
component of inhibitory tone. SICI is similar though it is thought to measure GABAA 
mediated inhibitory tone. ICF and sICF are faciliatory protocols that measure Excitatory 
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tone. The combination of these protocols is used to assess the state of the motor cortex 
and potentially surrounding areas.108 
In a study of the long term effects of mTBI and rmTBI, injury number and 
severity was directly correlated with the degree of increase over controls of the CSP.30 
Increased CSP suggests increased inhibitory tone as it takes longer for the baseline signal 
to return after stimulation. This same group looked again at patients acutely (w/in 72 hrs 
of injury) and compared them to patients seen upwards of 30 years after their injuries. 
When they assessed measures of inhibitory tone, using CSP and LICI, they found that 
increased inhibition was seen in the group later after injury but not as robustly in the 
acute phase.31 This suggests a progressive and durable change to brain conductance and 
inhibitory tone. 
Tallus et al. found an elevated RMT in patients with mTBI that persisted at least 
the average of five years after injury. RMTs were found to be about 10% machine output 
higher than uninjured controls. This suggests durable impaired conduction and decreased 
excitability.120 Impaired conduction could be due to shearing forces disrupting the 
permeability of membranes that govern the firing characteristics of neurons. 
In a longitudinal assessment of biomarkers by TMS, King et al. found a decrease 
in CSP and a decrease in SICI, pointing to an overall decrease in inhibitory tone in 
symptomatic concussed patients. This study also found an increase in sICF and ICF, 
suggesting an increased glutamatergic tone in the motor cortex of symptomatic concussed 
patients. Two similar populations showing different biomarkers suggest a trajectory of 
recovery assessable by TMS.62 This is one of the greatest strengths of this methodology 
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in that it can be assessed without invasive procedures and repeated as frequently as 
desired with no increased risk to the patient. Determining an appropriate biomarker for 
injury and recovery in this population would be hugely useful to reliably assess the status 
of this patient population. 
Increased neural excitability by decreased RMT was detected by TMS in 
concussed patients 72 hrs, 1 month, and 2 months after injury. This, and increased CSP, 
additionally support previous findings.35 
Separating CSP signals into ipsilateral (same side) and contralateral (opposite 
side) can assess the connectivity and functionality of the corpus callosum, the large white 
matter structure that connects the two hemispheres of the brain. As discussed earlier 
white matter seems to be affected differently by injury than grey matter and should be 
evaluated accordingly. Shorter contralateral CSP and ipsilateral CSP were observed in 
symptomatic concussed patients as well as increased hemispheric excitability. This 
suggests a loss of GABA-mediated inhibition.71 
Interestingly, increased cortical silent period (increased intracortical inhibitory 
tone) was found to be higher in mTBI patients when assessed by TMS 72 hrs, 1, 2, 4, and 
8 weeks after injury, contradicting other studies on similar populations. This 
contradicting information in the literature suggests that further study is required to 
accurately assess in which direction these biomarkers move. Consensus in the field would 
greatly improve the accurate assessment of injury/recovery and provide further 
confirmation of the biological underpinnings of disease. 
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Concussed patients show hypo-excitability by increased RMT with effects that 
last beyond 1-4 weeks from injury by TMS.103 This tracks with other studies of RMT but 
follows patients as long as four weeks. The presence of symptoms assessable by 
noninvasive brain stimulation that persist four weeks out from injury provide further 
evidence of longer lasting injury than the two weeks that is currently used for return-to-
play guidelines. 
TMS measures have been shown to accurately track with the severity of fatigue.98 
Fatigue is a general symptom that afflicts a large portion of this population, but may have 
varied biological bases. TMS’s ability to accurately track the resolution of these 
symptoms may aid in narrowing down the root cause of this common symptom and 
ultimately lead to better targeted interventions. These patients show dysfunctional 
inhibition as assessed by increased SICI and LICI ratios.99 Decreased inhibition when 
assessed through the lens of E/I balance results in increased excitation which has been 
shown in many animal models and tracks with the increased seizure susceptibility 
documented here. 
The use of TMS concurrently with EEG gives additional insight into the real-time 
spatially-constrained electrical activity of the brain. TMS EEG measures have further 
implicated GABAA mediated plasticity deficiencies in post concussive symptomology.95 
GABAA is the primary inhibitory receptor in the brain and any dysfunction would have 
widespread consequences. Its implication in this disease state both gives a target for 
influence and strengthens the association with dysfunctional cortical inhibition as a root 
of the symptomatology seen throughout this injury process. 
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Given the variability in results, accurate assessment of mTBI status by TMS is not 
established to the point of giving repeatable reliable results yet.67 However, the numbers 
point toward decreased inhibitory tone. To more accurately assess cortical inhibition, the 
paired pulse measures (SICI and LICI) which take into account two stimulations as 
opposed to one should be preferentially used. These measures assess inhibition while 
taking altered conductance into consideration. If conductance is altered due to injury, 
then each time the brain is stimulated the output is affected by the underlying integrity 
and functionality of the neural tissue. As this has been called into question by DTI 
studies, the use of SICI and LICI is preferred due to their use of internal controls, 
comparing two stimuli, and minimizing the influence of altered brain 
architecture/neuronal health across subjects. Decreased excitability by RMT, an increased 
Glu signal while symptomatic was found across multiple studies and support the findings 
of MacMullin et al.76 Confounds that limit measures like CSP and RMT, which are both 
measures extracted from a single stimulation, arise when altered conduction due to injury 
state is considered. Using conductance measures in various muscle groups may aid in the 
identification of this dysfunction. These measures have been standardized by length of 
limb to such a degree that impaired neural conduction may be able to be assessed as out 
of range.108  
 
EEG 
EEG is a powerful tool for assessing real time brain states during tasks. This 
makes it a valuable resource for assessing behavioral and cognitive functioning in mTBI 
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patients. When concussed patients were compared to earlier baseline measurement 
controls in an EEG odd-ball task study, concussed patients did not show the decrease in 
processing negativity that their earlier healthy selves had, suggesting longer-lasting 
memory and neurocognitive deficits that outlast other symptomology.66 This durable and 
pervasive change after injury continues to appear when objectively assessed by imaging 
techniques as opposed to self-report questionnaires. Durable subconscious change to the 
underlying biology necessitates better and more thorough imaging and monitoring and 
changes to the standard of care for this patient population. 
 
Molecular and behavioral consequences 
Unfortunately, the same insights with respect to proximity to symptoms and 
cellular expression of various target molecules are not as accessible in humans as they are 
in animal models. This necessitates that all pathologic data is postmortem irrespective of 
proximity to symptoms of interest. That being said, investigating the tissue health after 
death (often significantly temporally separated from injury) allows us to assess late-stage 
results of the cascade. Unfortunately, appropriate control is not always possible, but 
reasonable conclusions simply from the presence or absence of various markers can give 
insight to processes that were previously unknown. An analysis of postmortem brains 
with confirmed history of rmTBI found widespread DNA repair deficiencies with 
correlated increase in degree of proteinopathy. The presence of the APOE4 gene 
increases risk of neurodegeneration and protein deposition after mTBI. This gene is 
highly relevant to Alzheimer’s disease and the presence of Tau deposits. 
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Sleep abnormalities have been reported extensively as one of the distressing 
symptoms after a concussion. Reports of probable REM sleep behavior disorder, in which 
lack of REM sleep results in the body remaining active and mobile during sleep, has been 
associated with diseases of neurodegeneration and protein deposition. Recently, in a post 
mortem study of brains with a history of rmTBI and pRBD, this relationship was 
confirmed, suggesting that mTBI may initiate cascades that encourage neurodegeneration 
and protein deposition.2 A prior history of mTBI increases rates of depression and 
neuropsychiatric disease later in life,3 as well as an increase in suicidality.41 
 
RESULTS 
 The current state of research reveals a cascade from injury to epilepsy, with many 
points of potential intervention. Acceleration and deceleration of neural tissue cause 
forces that disrupt the integrity of cellular membranes of both neurons and endothelium. 
This disruption leads to changes in ion concentration intra and extracellularly, causing 
significant changes in cell metabolism and neurotransmission. These altered pathways are 
accompanied by microhemorrhages and exposure to substances normally contained 
within the vasculature. The presence of these foreign substances initiates an immune 
response within the brain causing the activation of astrocytes and microglia. This immune 
response further influences an already disturbed function of neurons in the injured area; 
however, due to the diffuse nature of the forces, these phenomena are felt to varying 
degrees across the brain. The increased demand for ATP production causes a significant 
uptick in the metabolic rate, which over time produces ROS and increases the burden of 
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oxidative stress. The GSH/GSSG system buffers this mounting stressor to the best of its 
ability, but due to an increase Glu transmission, less raw material is available to produce 
sufficient amounts of the primary antioxidant. Mounting oxidative stress degrades the 
extracellular matrices around vulnerable PVI, ultimately down regulating the expression 
of their signature protein that allows them to generate sufficient inhibitory tone. The drop 
in their function can be seen as a loss of gamma power on the EEG spectrum. In addition, 
malformed proteins begin to accumulate as a result of the already active immune 
response. This cascade progresses over time and creates an environment that predisposes 
the brain to future injury, each with increasingly severe symptoms, including the 




Figure 4 Acute injury, hours–days following TBI, induces Glu excitability and sclerosis. 
ROS are generated from the resulting hyperexcitability, promoting cellular dmage. As 
injury progresses days–weeks inflammation occurs exacerbating the damage caused by 
glutamate toxicity, and allow free iron to enter the cell. After months–years injury results 
in Tau aggregation. Tau interacts with zinc to generate further ROS increasing 
susceptibility to seizure.72  
	
 The understanding and characterization of this cascade is critical to the discovery of 
biomarkers and the design of treatments to reduce symptom severity, speed, recovery, 
and prophylax against long term serious consequences of injury. Catching epilepsy before 







When designing treatments, it is important to keep the global picture of mTBI in 
mind, both the distinction of symptoms verses cause, as well as the difference between 
primary and secondary injury. How each facet of the secondary injury modalities relate to 
one another is another critical lens to utilize when evaluating treatment. Currently, there 
are basic treatments that address symptoms associated with PCS, but very few address 
mechanisms that may prevent the continued potential development of PTE. There 
remains a critical need for interventions that treat current issues while preventing the 
evolution of new disease states. 
Thus far, there has been disappointing translation between animal studies and 
human outcomes, and this likely stems from a few places. Study designs on both sides 
and the limited consensus on the constraint of diagnosis make inclusion/exclusion criteria 
difficult to establish. The differences in size and structure of brains between animal 
models and humans may be one major issue due to the nature of the biophysics behind 
the injury, as the animal models, typically mice, are generally lissencephalic (smooth 
brained), while humans are profoundly gyrencephalic (convoluted brained). Different 
structures endure different forces and therefor, experience different degrees of injury. 
There has been increased use of pigs as an animal model for this type of injury, as they 
are much closer to humans in total body composition and are gyrencephalic, but because 
these studies are significantly more expensive and take far longer to run than mouse 
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studies, there is not yet a wealth of useable information. The heterogeneous nature of the 
injuries experienced by humans also complicates the picture further.69  
Regardless, as we learn about the biological underpinnings of disease and design 
treatments for those afflicted, it is important to maintain perspective. Treating symptoms 
is valuable and important, but treating underlying progression of biologic cascades must 
also be considered and addressed as equally if not more importantly. It is the difference 
between feeling okay when you are sick and never getting sick in the first place. 
Advances in monitoring technology, especially in contact sports, will give insight into 
what forces result in injury. These forces can be applied through new injury models, such 
as the CHIMERA, to replicate more precisely the conditions seen in real world scenarios. 
Currently, Valproate (VPA) is the only first-line antiepileptic drug and has been 
used to combat epileptogenesis.9 More definitive testing and study design needs to be 
done to better assess these effects. If intervening in the epileptogenic process is to be 
successful, understanding where in the timeline or what part of the cascade to interfere 
with is necessary. There is interplay between the various mechanisms and understanding 
how they affect each other is crucial to effective design of intervention. Treatments 
outside the first line AEDs should be considered in the treatment of this unique disease 







Blood pressure and systemic issues 
Another possibility is the use of drugs that modulate the brain’s relationship with 
the renin angiotensin system to modulate blood pressure and flow, in order to mitigate the 
spread of dysfunction through compromised vasculature.123 The use of statins to control 
BP during the post-injury phase is being investigated to mitigate hypoxic conditions and 
minimize the damage of compromised blood brain barrier (BBB). The use of 
Progesterone as a neuroprotective agent, as well as ciclosporin to mitigate mitochondrial 




Unmitigated inflammation can wreak havoc on the brain and cause long lasting 
damage which accumulates over time. Intervening early in the inflammation process to 
promote healing and prevent damage is critical for curbing this disease process and is 
likely to decrease the progression of mTBI to PTE. Below are a few treatments that 
address the inflammatory process that are under investigation. Minozac, an anti-
inflammatory drug that down regulates the expression of a broad range of cytokines to 
mitigate uncontrolled inflammation, has been used reasonably successfully to decrease 
glial activation and unchecked immune response to injury.22 
Administration of Glutathione, the primary antioxidant in the brain, has been 
shown not only to have some validity in staving off the destructive oxidative stress that 
progressively enhances symptoms, but also to outlast the physical and behavioral 
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symptoms of rmTBI.109 Other strategies in the future may include N-Acetyl Cysteine, 




Dysfunctional mitochondria impair cellular metabolism and energy production as 
well as produce ROS which promote oxidative stress. Recovering the function of these 
injured organelles can resolve symptoms and prevent progression of damage by oxidative 
stress. Metabolic changes can be assessed by calculating the resting metabolic rate. This 
calculation has been shown to correlate with both symptom severity and recovery status. 
Interestingly, a difference has been seen between men and women, in that women’s RMR 
returned to normal levels faster than men. Changes to diet may be advised to improve 
recovery time in accordance with metabolic need.127 Understanding the body’s needs for 
fuel during this period of recovery may aid in recovery time if supplemented 
appropriately, or serve as a biomarker of recovery. 
 
Drugs that influence neurotransmission 
The following animal studies have shown promise in treating various elements of 
the post-TBI cascade. Directly influencing aspects of deranged neurotransmission could 
quickly alleviate symptoms and if employed early enough in the injury progression 
timeline, may be the best way to prevent the ultimate emergence of more sinister disease.  
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Transcranial direct current stimulation (TDCS), another form of noninvasive brain 
stimulation, alone and in conjunction with Lorazepam, a benzodiazepine and first line 
antiepileptic drug, has been used successfully in mitigating seizure frequency and 
duration by modulating the GABA tone within regions of the brain.32 This is an exciting 
development combining stimulation and pharmaceutical intervention to enhance and 
localize the effects of either treatment. This may prove invaluable as more precise brain 
areas are identified as susceptible to epileptogenic change from mTBI. 
Huprazine, a potent acetylcholinesterase inhibitor, has been successfully used to 
increase the gamma band and rescue GABAergic intra-cortical inhibition in animals with 
severe TBI.43 The use of similar compounds later in the disease progression of mTBI may 
be effective in rescuing and potentially enhancing the GABAergic tone in those 
susceptible to PTE development. 
Ceftriaxone is a common Beta lactam antibiotic with potentially very interesting 
off target/ non-antibiotic effects including the upregulation of GLT-1. After severe TBI, 
administration of ceftriaxone has been shown to preserve expression of GLT-1.45 This 
prevents the excitotoxic pressures acutely after TBI, ultimately preserving PV expression 
in PVI49 and preserving intracortical inhibitory tone as assess by TMS.45,49 
The use of Memantine, an NMDA antagonist, has been used somewhat 
successfully in a mouse model of rmTBI. Acute administration of Memantine was shown 
to mitigate some of the excitotoxic effects as well as decreased Tau expression and glial 
response to injury assessed 1 month after the last impact. However, behavioral deficits 




Mental fatigue and inability to focus are among the most common symptoms in 
PCS. Methylphenidate, a common drug prescribed for Attention Deficit Disorder, has 
been used to successfully curb the executive functioning issues associated with post-
concussion syndrome. Although the chronic use of these drugs may prevent the brain 
from returning to its baseline state of neurotransmission, stimulants in this class of drugs 
are one of the most prescribed in the world and have been shown to be safe if used as 
prescribed. Use of these drugs in the acute phase may mitigate loss of class time for 
young people and time off work for adult patients as their focus should be somewhat 
preserved by this intervention. This treatment addresses symptoms only and likely 
provides no influence on the progression towards epilepsy.  
Sleep deficiencies may be addressed by supplementing brain derived neurotrophic 
factor (BDNF) which has been shown to have potent neuroprotective properties as well 
as alpha melanocyte stimulating hormone to re-establish healthy sleep cycles.115 Early 
intervention with BDNF may reduce long term inflammatory consequences by quieting 
the inflammasome and promoting cellular resistance. 
 
Progressive issues 
The prevention of Tau accumulations has been recently addressed by the design 
and administration of anti-pTau antibodies that bind to the monomers and prevent 
aggregation. These abs have been shown to successfully mitigate accumulation of pTau 
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and prevented deficiencies in behavior and memory as well as cellular functioning as 
assessed by electrophysiology when administered acutely after injury.64  
DNA repair deficiencies may be ameliorated by gene therapy modalities or the 
administration of factors that upregulate the expression of critical proteins to brain health 
such as myelin basic protein to preserve cortical connectivity and insulation and prevent 
the slowing of signal propagation that emerges later in life.112 
 
CONCLUSION 
	 This work points towards mechanisms that link mTBI to PTE through the loss of 
cortical inhibition and increase in oxidative stress and gliosis, which overtime increases 
Glu/GABA ratio, resulting in an increased risk of developing epilepsy. Better 
understanding of the anatomy and progression of the injury and establishing trajectories 
to better identify those at risk for long term consequences is critical for the management 
of resources to make meaningful progress in this field of research. The investigation of 
the various biological mechanisms that links concussion and epilepsy is a critical step in 
developing treatment strategies and prophylaxis that could prove to be crucial for so 
many. Any small increase in prevalence pursuant to concussion will affect millions of 
lives due to high incidence of mTBI. Many systemic issues exist within the definition and 
capture of this diverse and enormous patient population. The continued research into the 
relationship between various symptomologies and their relation to each other will better 
elucidate how to intervene and effectively treat and protect those suffering from this 




Table 1.  First line Prophylactic treatment for PTE including their mechanism and 
side effects modified from Lucke-Wold et al. 2015.72 
Anticonvulsant 
Drug 
Mechanism Adverse Reactions 
Phenytoin Stabilize inactive form of sodium 
channel 
Increase level of stimulation required to 





Carbamazepine Stabilize sodium channels in inactive 
state 
Increase level of stimulation required to 







Phenobarbital Activate GABA receptors, Inhibit 
calcium channels 
Cl- into cell via GABAr channels, 
increasing inhibitory effect 
Ca+ entry is critical to releasing 






Valproate 1.Inhibit sodium channels, and 2.GABA 
transaminase, 3. Activate GABA 
synthetic enzyme glutamic acid 
decarboxylase, 4. alter the conductance 
of calcium and 5. potassium 
1. Increase level of stimulation required 
to depolarize cells effected 
2. Inhibition of GABA transaminase 
increases levels of GABA, hence 
increasing inhibitory tone 






Changes in ion conduction effect 
thresholds at which functions occur such 





Glasgow Coma Scale 
 
Eye Opening Response 
• Spontaneous--open with blinking at baseline 4 points 
• To verbal stimuli, command, speech 3 points 
• To pain only (not applied to face) 2 points 
• No response 1 point 
 
Verbal Response 
• Oriented 5 points 
• Confused conversation, but able to answer questions 4 points 
• Inappropriate words 3 points 
• Incomprehensible speech 2 points 
• No response 1 point 
 
Motor Response 
• Obeys commands for movement 6 points 
• Purposeful movement to painful stimulus 5 points 
• Withdraws in response to pain 4 points 
• Flexion in response to pain (decorticate posturing) 3 points 
• Extension response in response to pain (decerebrate posturing) 2 points 




Teasdale G, Jennett B. Assessment of coma and impaired consciousness. Lancet 1974; 
81-84. 
Teasdale G, Jennett B. Assessment and prognosis of coma after head injury. Acta 
Neurochir 1976; 34:45-55. 
Categorization: 
Coma: No eye opening, no ability to follow commands, no word verbalizations (3-8) 
Head Injury Classification: 
Severe Head Injury----GCS score of 8 or less 
Moderate Head Injury----GCS score of 9 to 12 
Mild Head Injury----GCS score of 13 to 15 
(Adapted from: Advanced Trauma Life Support: Course for Physicians, American 
College of Surgeons, 1993). 
Disclaimer: 
Based on motor responsiveness, verbal performance, and eye opening to appropriate 
stimuli, the Glascow Coma Scale was designed and should be used to assess the depth 
and duration coma and impaired consciousness. This scale helps to gauge the impact of a 
wide variety of conditions such as acute brain damage due to traumatic and/or vascular 
	
56 
injuries or infections, metabolic disorders (e.g., hepatic or renal failure, hypoglycemia, 
diabetic ketosis), etc. 
Education is necessary to the proper application of this scale. 
Teasdale G, Kril-Jones R, van der Sande J. Observer variability in assessing impaired 
consciousness and coma. J Neurol Neurosurg Psychiatry 1978; 41:603-610; Rowley G, 
Fielding K. Reliability and accuracy of the Glasgow Coma Scale with experienced and 
inexperienced users. Lancet 1991; 337:535-538). The predictive value of the GCS, even 
when applied early, is limited (Waxman K, Sundine MJ, Young RF. Is early prediction of 
outcome in severe head injury possible? Arch Surg 1991; 126:1237-1242). 
Despite these and other limitations (Eisenberg HM. Outcome after head injury: Part I: 
general Considerations, in Becker DP, Povlishock JR (eds): Central Nervous System 
Trauma Status Report, 1985. Washington, DC: U.S. Government Printing Office, 
1988:271-280), health care practitioners continue to use this practical scale widely. 
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